Newborn Screening Market - By Product Type (Instruments, Consumables), Technology (Tandem Mass Spectrometry, Oximetry, Enzyme-Based Assays, DNA Assays), Test Type (Dried Blood Spot, Hearing Screening, CCHD), End-use – Global Forecast, 2024 – 2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationNewborn Screening Market - By Product Type (Instruments, Consumables), Technology (Tandem Mass Spectrometry, Oximetry, Enzyme-Based Assays, DNA Assays), Test Type (Dried Blood Spot, Hearing Screening, CCHD), End-use – Global Forecast, 2024 – 2032
Newborn Screening Market Size
Newborn Screening Market size was valued at USD 950.5 million in 2023 and is estimated to grow at 7.7% CAGR from 2024 to 2032 due to the rising incidence of genetic and metabolic diseases.
The growing burden of congenital disorders detected at birth is driving the demand for several screening tests. Hospitals and healthcare providers are increasingly adopting advanced screening technologies to identify these disorders early for ensuring timely intervention and treatment.
| Report Attribute | Details |
|---|---|
| Base Year | 2023 |
| Newborn Screening Market Size in 2023 | USD 950.5 Million |
| Forecast Period | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR | 7.7% |
| 2024 – 2032 Value Projection | USD 1.8 Billion |
| Historical Data for | 2018 – 2023 |
| No. of Pages | 150 |
| Tables, Charts & Figures | 134 |
| Segments covered | Product Type, Technology, Test Type, End-use, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Rapid technological advancements are improving the accuracy and efficiency of screening methods. Moreover, expanded screening programs will enhance the ability to detect and manage newborn disorders effectively. For instance, in March 2024, WHO reported that the first month is the most vulnerable for child survival, with 2.3 million newborns dead in 2022, subsequently highlighting the critical need for effective newborn screening to improve early detection and intervention.
More and more governments are realizing how important it is to screen newborns for genetic, metabolic, and congenital disorders. Because of this, they're putting in place rules and programs that make newborn screening mandatory in different areas. Hospitals and clinics are now using more comprehensive screening programs because of these government initiatives. These programs help identify and treat genetic, metabolic, and congenital disorders as early as possible. This can make a big difference in a child's health. Governments are continuing to notice how important it is to diagnose these disorders early. They're making and enforcing policies to make sure that more babies get screened. This government support is helping newborn screening programs reach more people and get better at improving public health. For example, the Alabama Bureau of Clinical Laboratories (BCL) runs all newborn blood screenings in Alabama. Every year, they test about 60,000 babies and handle 150,000 samples.
However, limited infrastructure and the shortage of skilled professionals are impeding newborn screening efforts. These challenges are continuing to hamper the widespread implementation and effectiveness of screening programs. Without adequate resources and expertise, early detection and intervention will remain compromised, potentially leading to preventable health complications and increased infant mortality rates, restricting the industry expansion to some extent.
Newborn Screening Market Trends
With companies increasingly launching advanced devices to improve early detection of genetic disorders in infants, the market is set to witness steady growth. These innovative screening tools are enhancing diagnostic accuracy and accessibility. The ongoing technological advancements are making way for the rising awareness among healthcare providers and parents.
The continuous development of more efficient and reliable screening solutions are ensuring better health outcomes for newborns worldwide. This innovation will transform newborn screening practices for making early detection and intervention more effective and widespread. For instance, in September 2023, Mylab launched MyNeoShield, a point-of-care newborn screening device for revolutionizing newborn healthcare by providing faster, more accessible, and cost-effective screening for saving lives and preventing lifelong illnesses through early detection and intervention.
Newborn Screening Market Analysis
On the basis of product type, the industry size from the instruments segment is poised for significant growth at 7.8% CAGR through 2032. Clinics are increasingly employing sophisticated instruments for newborn screening to detect metabolic and genetic disorders early. These instruments help analyze blood samples from newborns to identify conditions like cystic fibrosis and hypothyroidism. By utilizing advanced technology, they are enabling prompt diagnosis and intervention. Moreover, medical facilities are integrating more precise and comprehensive instruments, further adding to the segment growth.
Based on technology, the newborn screening market value from the tandem mass spectrometry segment is predicted to record USD 476 million by 2032. This expansion is due to the robust role of tandem mass spectrometry in transforming newborn screening by analyzing blood samples for metabolic disorders. It helps detect multiple conditions from a single sample for providing rapid and accurate results. This technology also assists in identifying biomarkers of rare diseases and ensuring early intervention and treatment.
Based on test type, the dried blood spot segment accounted for USD 412.5 million in 2023 and may exhibit 8.1% CAGR through 2032. Dried blood spot (DBS) sampling involves collecting a small amount of blood from a newborn's heel onto a special filter paper. It enables healthcare providers to conduct screenings efficiently and accurately. With its simplicity and effectiveness, DBS sampling has become indispensable in identifying a wide range of genetic disorders and metabolic conditions early on for ensuring timely intervention and better health outcomes for newborns.
As more and more hospitals adopt newborn screening programs to catch health problems in babies early on, the market for these programs is predicted to grow to around $859 million by 2032. Doctors and nurses are regularly taking samples from newborns and using different tests to check for genetic and metabolic disorders right away. Hospitals are also making newborn screening a top priority by bringing in new technology and making their procedures better to get more accurate and complete results. This focus on newborn screening is improving the health of babies by allowing for early interventions and support for families. It's also helping to raise the standard of care for newborns and improve their overall health outcomes.
North America newborn screening market is predicted to record over USD 837 million by 2032, on account of the increasing advancements in diagnostic techniques and the expansion of screening panels. Healthcare providers in the region are integrating innovative methods for more precise and comprehensive screening of newborns. Ongoing R&D efforts are enhancing diagnostic capabilities and broadening the scope of screening panels. These advancements will enable early detection of a wider range of genetic disorders and metabolic conditions for improving health outcomes for newborns across North America through timely intervention and personalized treatment strategies.
Newborn Screening Market Share
Leading industry players are developing innovative technologies and solutions to expand their portfolio. They are collaborating with healthcare providers to enhance screening accuracy and accessibility. These players are also introducing advanced methods and expanding their global reach to ensure early detection and intervention for newborns worldwide.
Newborn Screening Market Companies
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- GE Healthcare
- Masimo Corporation
- Medtronic plc
- Natus Medical Incorporated
- PerkinElmer, Inc.
- Thermo Fisher Scientific Inc.
- Trivitron Healthcare
- Waters Corporation
Newborn Screening Industry News
- In January 2023, Masimo unveiled an advanced baby monitoring system for allowing caregivers to track the data of infants instantly.
- In November 2023, Trivitron Healthcare introduced EkSahiShuruat, a campaign dedicated to increasing awareness about newborn screening in India. The initiative is aimed at disseminating information widely and emphasizing the vital significance of newborn screening across the country.
Newborn screening market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
Market, By Product Type
- Instruments
- Dried blood spot puncher
- Hearing screening devices
- Analyzers
- Electrophoresis unit
- Pulse oximetry
- Other instruments
- Consumables
Market, By Technology
- Tandem mass spectrometry
- Oximetry
- Enzyme-based assays
- DNA assays
- Other technologies
Market, By Test Type
- Dried blood spot
- Hearing screening
- Critical congenital heart defect (CCHD)
- Other test types
Market, By End-use
- Hospitals
- Diagnostic centers
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East and Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy